NCT05791474撤回1 期
A Phase Ia Trial of ATI-2231 in Advanced Solid Tumor Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Number of participants experiencing adverse events
研究概览
简要总结
The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven advanced solid tumor malignancy including head and neck cancer, non-small cell lung cancer, gastrointestinal adenocarcinoma, pancreatic adenocarcinoma, prostate cancer, bladder cancer, and breast cancer.
- •Eligible patients must have an advanced solid malignancy above, for which standard curative or palliative therapies do not exist or are no longer effective.
- •Measurable or non-measurable but evaluable disease by RECIST v 1.
- •Patients must have archival tissue sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.
- •At least 18 years of age.
- •ECOG performance status ≤ 2
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow and organ function as defined below:
- •Leukocytes ≥ 3 K/cumm
- •Absolute neutrophil count (ANC) ≥ 1.5 K/cumm
- •Platelets ≥ 100 K/cumm
- •Total bilirubin ≤ 1.5 x IULN (unless patient has known Gilberts disease)
- •AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- •Creatinine clearance > 60 mL/min by Cockcroft-Gault
- •The effects of ATI-2231on the developing human fetus are unknown. For this reason, women of childbearing potential and men who are heterosexually active must agree to use adequate contraception as specified in the protocol. Contraception should continue for 1 month (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Ability to understand and willingness to sign an IRB approved written informed consent document.
排除标准
- •Patients may not have received the following investigational or SOC therapies within the below specified time frames prior to C1D1:
- •Denosumab or bisphosphonates within 4 weeks
- •Radiation therapy within 1 week
- •Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
- •Immunotherapy within 3 weeks
- •Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
- •Endocrine therapies do not have a required washout and may be continued until C1D
- •Untreated brain metastases. Patients with treated brain metastases are eligible if they show no evidence of progression and are off steroids or on stable/decreasing steroid dose.
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ATI-
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
- •Patients with known HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
- •Screening resting QTcF above 460 ms (average of triplicate).
研究组 & 干预措施
ATI-2231 monotherapy dose escalation
Experimental
- Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day.
- Each cycle is 21 days
干预措施: ATI-2231 (Drug)
结局指标
主要结局
Number of participants experiencing adverse events
时间窗: From baseline through 30 days after end of treatment (estimated to be 7 months)
-Graded per CTCAE v. 5.0
次要结局
- Changes in ATI-2231 pharmacokinetics (PK) as measured by half-life (T1/2)(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-24h)(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, and 24 hours post dose cycle 1 (estimated to be 1 day))
- ATI-2231 pharmacokinetics (PK) as measured by trough concentration(Cycle 6 day 1 (each cycle is 21 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)(Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by elimination rate constant(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent volume of distribution(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-infinity)(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent clearance(Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)(Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t)(Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours))
- Changes in ATI-2231 pharmacokinetics (PK) as measured by trough concentration(Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours))
研究者
相似试验
终止
1 期
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasAdvanced Solid TumorMetastatic Solid TumorMature B-cell Non-Hodgkin LymphomaNCT04986865Antengene Biologics Limited31
招募中
1 期
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell LymphomaAdvanced Solid TumorsRelapsed/Refractory B-cell LymphomaNCT06445517InSilico Medicine Hong Kong Limited60
终止
1 期
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasAdvanced Solid TumorMetastatic Solid TumorMature B-cell Non-Hodgkin LymphomaNCT05490043Antengene (Hangzhou) Biologics Co., Ltd.33
终止
1 期
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsSolid TumorNCT06336148Actym Therapeutics, Inc.10
招募中
1 期
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04947033I-Mab Biopharma US Limited25